Nigerija - anglų - NAFDAC (National Agency for Food and Drugs Administration and Control)

paracetamol 500mg caffeine 30mg

Australija - anglų - APVMA (Australian Pesticides and Veterinary Medicines Authority)

norbrook laboratories australia pty limited - oxfendazole - parasiticides - goat | sheep | billy | buck | capra hircus | doe | ewe | hogget | kid | lamb | ovine | ram | weaner | wether - barber's pole worm - haemonchus spp. | black scour worm - trichostrongylus spp. | large mouth bowel worm - chabertia spp. | lungworm - dictyocaulus spp. | nodule worm - oesophagostomum spp. | small brown stomach worm-ostertagia spp. | small intestinal worm - cooperia spp. | tapeworm - moniezia spp. | thin necked intestinal worm | threadworm - capillaria spp. | whipworm - trichuris spp. | hair worm | intestinal hair worm | pole worm | small hair worm | tapeworm - heads/segments | teladorsagia

Nigerija - anglų - NAFDAC (National Agency for Food and Drugs Administration and Control)

paracetamol 500mg, diclofenac 50mg

Bangladešas - anglų - DGDA (Directorate General of Drug Administration)

pristine pharmaceuticals - diclofenac sodium - capsule - 100 mg

Pietų Afrika - anglų - South African Health Products Regulatory Authority (SAHPRA)

litha pharma (pty) ltd - tablet - not indicated - none

Nigerija - anglų - NAFDAC (National Agency for Food and Drugs Administration and Control)

ibuprofen 200mg, paracetamol 325mg

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - mefloquine hydrochloride (unii: 5y9l3636o3) (mefloquine - unii:tml814419r) - mefloquine hydrochloride 250 mg - treatment of acute malaria infections :  mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of p. falciparum (both chloroquine-susceptible and resistant strains) or by plasmodium vivax. there are insufficient clinical data to document the effect of mefloquine in malaria caused by p. ovale or p. malariae.   note: patients with acute p. vivax malaria, treated with mefloquine, are at high risk of relapse because mefloquine does not eliminate exoerythrocytic (hepatic phase) parasites. to avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). prevention of malaria :  mefloquine hydrochloride tablets are indicated for the prophylaxis of p. falciparum and p. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of p. falciparum. use of mefloquine hydrochloride tablets is contraindica

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

h.j. harkins company, inc. - mefloquine hydrochloride (unii: 5y9l3636o3) (mefloquine - unii:tml814419r) - mefloquine hydrochloride 250 mg - mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of p. falciparum (both chloroquine-susceptible and resistant strains) or by plasmodium vivax . there are insufficient clinical data to document the effect of mefloquine in malaria caused by p. ovale or p. malariae . -  note: patients with acute p. vivax malaria, treated with mefloquine hydrochloride tablets, are at high risk of relapse because mefloquine hydrochloride tablets do not eliminate exoerythrocytic (hepatic phase) parasites. to avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). mefloquine hydrochloride tablets are indicated for the prophylaxis of p. falciparum and p. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of p. falciparum . use of mefloquine hydrochloride tablets is contraindicated in patients

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

rebel distributors corp - mefloquine hydrochloride (unii: 5y9l3636o3) (mefloquine - unii:tml814419r) - mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of p. falciparum (both chloroquine-susceptible and resistant strains) or by plasmodium vivax . there are insufficient clinical data to document the effect of mefloquine in malaria caused by p. ovale or p. malariae . -  note: patients with acute p. vivax malaria, treated with mefloquine hydrochloride tablets, are at high risk of relapse because mefloquine hydrochloride tablets do not eliminate exoerythrocytic (hepatic phase) parasites. to avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). mefloquine hydrochloride tablets are indicated for the prophylaxis of p. falciparum and p. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of p. falciparum . use of mefloquine hydrochloride tablets is contraindicated in patients